基于单细胞测序技术分析上皮细胞相关基因与卵巢癌患者预后的关系

Correlation between Epithelial Cell Related Genes and Prognosis of Patients with Ovarian Cancer based on Single Cell Sequencing

目的基于上皮细胞标志物的表达构建1个多基因风险评分来评估卵巢癌患者的预后。方法对卵巢癌单细胞测序数据进行降维、聚类,识别上皮细胞标记物、恶性和非恶性标记物。使用回归分析筛选与预后相关的上皮细胞标记基因以构建风险评分模型,基于风险评分将患者分为高、低风险(H.Risk、L.Risk)组,用于预测卵巢癌患者的预后。结果构建了1个4个基因(EPCAM、CLDN4、CXCR4和TIMP3)的风险评分模型。生存分析表明在试验队列和验证队列中H.Risk组患者的OS均比L.Risk组患者差(P<0.05)。途径富集分析显示,高、低风险组之间的差异基因与免疫抑制和恶性进展相关,包括细胞粘附、细胞外基质、神经活性配体-受体相互作用、钙信号通路、转化生长因子-β等。结论通过bulkRNA-seq和scRNA-seq数据的综合分析提出了1种基于上皮细胞亚群标记基因的风险评分模型,并可能为卵巢癌患者提供潜在的治疗靶点。

Objective To construct a polygenic risk score based on the expression of epithelial cell markers to evaluate the prognosis of patients with ovarian cancer.Methods The single cell sequencing data of ovarian cancer were reduced and clustered to identify epithelial cell markers,malignant and non-malignant markers.Regression analysis was used to screen epithelial marker genes related to prognosis to construct a risk score model.Based on the risk score,patients were divided into high risk group and low risk group(H.Risk,L.Risk)to predict the prognosis of patients with ovarian cancer.Results A risk scoring model with four genes(EPCAM,CLDN4,CXCR4 and TIMP3)was constructed.Survival analysis showed that the OS of patients in H.Risk group was worse than that in L.Risk group in trial cohort and verification cohort(P<0.05).Pathway enrichment analysis showed that the differential genes between high and low risk groups were associated with immunosuppression and malignant progression,including cell adhesion,extracellular matrix,neuroactive ligand-receptor interaction,calcium signal pathway,transforming growth factor-β.Conclusion Through the comprehensive analysis of bulkRNA-seq and scRNA-seq data,a risk scoring model based on epithelial cell subsets marker genes is proposed,which may provide potential therapeutic targets for patients with ovarian cancer.